


Centers for Disease Control (CDC) (1996) Comprehensive plan for epidemiologic surveillance. CDC, Atlanta, GA.


Guyatt, G.H., Sackett, D.L., Cook, D.J. (1994) Users’ guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 271(1):59-63.


Health Professionals Follow-up Study (2010): http://www.hsph.harvard.edu/hpfs/.


Hippocrates (1938) On airs, waters, and places. Translated and republished in Medical Classics 3:19–42.


National Health and Medical Research Council (NHMRC) (1991) Guidelines on ethical matters in Aboriginal and Torres Strait Islander health research. NHMRC, Canberra.

National Health and Medical Research Council (NHMRC) (2003) Values and ethics: Guidelines for ethical conduct in Aboriginal and Torres Strait Islander health research. NHMRC, Canberra.

National Health and Medical Research Council (NHMRC) (2005) Keeping research on track. A guide for Aboriginal and Torres Strait Islander peoples about health research ethics. NHMRC, Canberra.


<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aboriginal and Torres Strait Islander people ethics in health research</td>
<td>499-501</td>
</tr>
<tr>
<td>Aboriginal communities</td>
<td>26</td>
</tr>
<tr>
<td>accuracy, routine collected health data</td>
<td>186</td>
</tr>
<tr>
<td>active surveillance</td>
<td>183</td>
</tr>
<tr>
<td>actual reproductive rate</td>
<td>66</td>
</tr>
<tr>
<td>adjectival scale</td>
<td>417</td>
</tr>
<tr>
<td>Advanced Questionnaire Design</td>
<td>402</td>
</tr>
<tr>
<td>aetiology of disease</td>
<td>41-5</td>
</tr>
<tr>
<td>Henle and Koch's causality criteria</td>
<td>41-2</td>
</tr>
<tr>
<td>necessary, sufficient and contributory factors</td>
<td>42-5</td>
</tr>
<tr>
<td>agent (epidemiological triangle)</td>
<td>52-4</td>
</tr>
<tr>
<td>agreement and equivalence, pitfalls of</td>
<td>459-61</td>
</tr>
<tr>
<td>alpha error (Type I error)</td>
<td>453-4</td>
</tr>
<tr>
<td>Altman, Douglas</td>
<td>164</td>
</tr>
</tbody>
</table>
| Alzheimer's disease (case study)                         | 84, 228-9, 404\
| analysis                                                 | 244-7\
| unit of 172, 204                                          |      |
| analytical studies                                        | 171, 216-17|
| appropriateness, routine collected health data            | 187  |
| Aristotle                                                 | 503  |
| ASPREE (Aspirin in Reducing Events in the Elderly)        | 235  |
| asymptomatic carrier                                      | 56   |
| attack rate                                               | 54   |
| attributable risk                                         | 247, 298-9, 300, 301, 302\
| Australian Institute of Health and Welfare (AIHW)        | 173  |
| Australian New Zealand Clinical Trials Registry (ANZCTR)  | 248  |
| authors, instructions for                                | 524  |
| authorship                                                | 520  |
| autonomy, respect for (ethics)                            | 490-2|
| backward directionality                                   | 262  |
| basic reproductive rate                                   | 65, 66, 67, 68, 70, 80|
| before-and-after controls (experimental studies)         | 227-9|
| Belmont Report                                            | 489  |
| benefice                                                  | 492  |
| Bentham, Jeremy                                           | 504  |
| Berkson's fallacy                                         | 279, 329, 331-5|
| beta error (Type II error)                               | 453-4|
| bias                                                      |      |
| concept of 319-28                                         |      |
| confounding 325, 326, 344-57                             |      |
| control of 357-60                                         |      |
| definition 324                                           |      |
| detection 335-6, 342                                      |      |
| direction of 360-4                                       |      |
| information 325, 326, 338-44, 357, 358, 359, 363, 408, 533, 541 |      |
| selection 325, 326, 328-38, 342                           |      |
| self-selection 336-7                                      |      |
| volunteer 104, 329-31                                     |      |
| biological agents, characteristics of 53-4               |      |
| biomedical ethics, principles of 489-96                  |      |
| beneficence                                              | 492  |
| confidentiality                                           | 494-5|
| fidelity                                                  | 494  |
| good epidemiological practice 495-6                      |      |
| informed consent                                         | 490-1|
| justice 492-4                                            |      |
| non-malfeasance                                          | 492  |
| privacy 494-5                                            |      |
| respect for autonomy                                      | 490  |
| veracity 494                                             |      |
| births registration                                       | 180, 188|
| bivariate statistical test                                | 455-9|
| Bland, Martin                                             | 164  |
| blind trials                                              | 236-7|
| blinding (masking)                                       | 236-7, 255, 358, 522|
| bubonic plague                                            | 50-1 |
| Buell, Philip                                             | 177  |
| Busselton Health Study                                    | 269  |
| Butlin, Henry                                             | 21   |
| cancer registration                                       | 181  |
| Carotene and Retinol Efficacy Trial (CARET)               | 246  |
carriers 56
Carroll, Kenneth K. 192–3
carry-over effect 239
case investigation 59–60
case reports 200–1
case series 200–1
case–control studies 265, 266, 273–81, 290–1, 294, 302–3, 304, 358–9
matching in 280–1
categorical data 415, 435
categorical variable 435, 440, 458, 463
causal web 44, 46, 52
causality (disease aetiology)
epidemiological approach to 45–9
Henle and Koch’s causality criteria 41–2
census information 179–80
Centers for Disease Control and Prevention (USA) 25, 182, 190, 192, 200–1, 336
cervical cancer 40
Chadwick, Edwin 22
*Chlamydia trachomatis* 83, 103, 114, 117–18, 175
cholera 51
chronic disease 5, 38, 271
CINAHL 154
classical public health epidemiology 11–12
clinical epidemiology 11–12
*Clinical Epidemiology* 12, 170, 336
clinical equipoise 498–9
clinical research, ethical concerns in 498–9
clinical trial 220–1, 498–9
closed cohort 123–4, 287–8, 297, 298
cluster sampling 382–5
Cochran, William 376
Cochrane, Archie 155, 156
Cochrane Collaboration 155
coding 415, 462, 463
coercion and ethics 301–2
cohort
closed 123–4, 287–8, 297, 298
dynamic 124, 272, 297–8
fixed 123–4, 297–8
studies 265, 267–73, 287–90, 297–301, 358
communicable disease see infectious disease
communitarianism 505–6
community trial 220–1
comparative epidemiological study 8
complete observer 406
complete participant 405
completeness, routine collected health data 186–7
compliance (experimental studies) 243–4
computer programs for data analysis 469
conceptual research hypothesis 16, 17, 151–2, 161, 163, 164
confidence interval (CI) 442–3
for the odds ratio 448–50
and population mean 443–5
for the relative risk 447–8
width of a 445–7
confidentiality 494–5
confounding bias 325, 326, 344–57
Consolidated Standards of Reporting Trials (CONSORT) checklist 248, 521–3
convenience sampling 385, 396
coronary heart disease (CHD) 246–7, 271
correlation matrix (multivariable statistical analysis) 462–3
criteria of causation 45–6
critical appraisal 322, 526
and literature review 157, 158–9
of published articles 529–44
cross-over trial 238–9
cross-sectional studies 115, 201–5, 214, 265, 266, 294–5, 338, 352–4, 376, 378
comparative 281–7
and control of bias 359
definition 201–2, 281–2
descriptive 201–4
general comments 204–5
general statements about 283–4
and sample size calculation 389–2
cumulative incidence 54, 120–3, 124, 128, 297
cyclical time trends 177
data analysis, computer programs for 469
data
categorical 415, 435
numerical 415, 435
protective 401
types of qualitative 434–6
see also health data
data collection, quantitative methods of 399–424
adjectival scale 417
considerations for rating scales 418
the ‘don’t know’ problem 421
effect of wording on responses 422
face-to-face interviews vs distance interviews 407–8
features of a good question 412–14
format of responses 414–16
interviews 406–8
Likert scale 417
numerical rating scale (NRS) 416–17
observations 403–6
quality of data 400–3
questionnaire design 409, 411
questionnaire structure 409–10
questionnaires 408–19
recall loss 422–3
Index

data collection, quantitative methods of cont.
  recording interview information 408
  reliability 400
  semantic differential scale 418–19
  telescoping error 422–3
  validating instruments 419–21
  validity 400
  vignettes 419
  visual analogue scale (VAS) 416–17
  what can go wrong 421–3
deaths registration 180, 188
debriefing 497–8
decreation and ethics 501–2
Declaration of Geneva 488
Declaration of Helsinki 485, 488, 494
derrick, Edward 38

descriptive cross-sectional studies 201–4
descriptive data
  routine health statistics 178–85
descriptive epidemiology 172–8
  characteristics of ‘person’ 173–5
  characteristics of ‘place’ 175–7
  characteristics of ‘time’ 177–8
descriptive statistics 436–41
  calculating 25% and 75% quantiles 438–40
  calculating the arithmetic mean 436
  calculating a median 436
  calculating a standard deviation 438
definition 434
descriptive studies 8, 170–2, 201, 216
cross-sectional studies 201–4
design options for experimental studies 223–9
  before-and-after controls 227–9
  historic controls (non-current controls) 224–5
  randomised control trial (RCT) 229, 234–6
  research-decided control group 226–7
  volunteer control group 226–7
detection bias 335–6, 342
determinant-centred epidemiology 11
determinism 15, 41
diagnosis 82–3
diagnostic test calculations
  dependence on predictive values on
  prevalence 93–5
  positive and negative predictive
  values 89–90
  predictive values from sensitivity and
  specificity 90–3
diagnostic tests 82
  assessing reliability 84–6
  assessing validity 86–90
  optimal cut-off point 96–9
  quality measures of 83–4
  receiver operating characteristics 96–9
  reliability 83–4
  sensitivity 86, 87–9, 90–3
  specificity 86, 87–9, 90–3

validity 83–4
validity terminology 86–7
directionality (observational study
design) 261–2, 264–5, 266–7
disease
  aetiology of 41–5
  aetiology and ecological studies 199–200
  and disease aetiology 199
  four main stages of 37
  germ theory of 5, 19–20, 42
  natural history of 6, 37–41, 218
  notifiable, registration of 181
  outbreak 59
  prevention 40
  status, misclassification of 339–41
  time periods 39–40
  timeline 37–8
see also infectious disease; screening for disease
disease frequency, measures of 113–39
  characteristics of prevalence 117–18
  count, population size and time 114
  incidence 119–29
  point and period prevalence 115–16
  prevalence 115–19
  relationship between prevalence and
  incidence 129–33
standardisation of rates 132–9
disease-centred epidemiology 11
disease-specific defence mechanisms 55
distant interviews 407–8
Doll, Richard 6, 24, 27, 271, 275
double-blind trials 236–7
Down syndrome 103, 225
Dunn, John 177
Durkheim, David Emile 197
dynamic cohorts 124, 272, 297–8
ecological (correlation) studies 192–200
  and disease aetiology 199
  limitations 195–9
ecological fallacy 197–9
empiricism 15
endemic 4, 51, 87
environment (epidemiological triangle) 56
epidemic 59
epidemic curve 61–5
  of a continuous source outbreak 63
  of a person-to-person outbreak 63–5
epidemiological approach to causality 45–9
epidemiological process 13–18, 149
epidemiological practice, good 495–6
epidemiological transition 5, 51
epidemiological triangle (agent-host-
environment) 52–6
epidemiology
  classification of 7–13
  clinical 11–12
definition 2-7

descriptive 172-8

determinant-centred 11

disease-centred 11

history of 18-24

infectious disease 4, 56-9, 65, 70

major achievements in public health 25-8

molecular 44

qualitative 8

quantitative 8, 9, 406

equivalence and agreement, pitfalls of 459-61

error

alpha (Type I) 453-4

beta (Type II) 453-4

random 321, 322-3, 326, 349, 433, 441-2, 451, 452

systematic 321, 322-3, 326, 339, 341, 349

telecomping error 422-3

errors in statistical testing 453-4

ethical theory and public health 503-6

communitarianism 505-6

liberalism 504-5

utilitarianism 503-4

ethics

biomedical, principles of 489-96

and clinical research 498-9

correction and deception 501-2

debriefing 497-8

definition 483-4

health research (Aboriginal and Torres Strait Islanders people) 499-51

health research (historical perspective) 484-9

issues in health research 496-9

Milgram experiment 486-7

Nuremberg Code (1947) 487-9

quality research 497

responsibility 496-7

scientific misconduct 502-3

ethics, principles of biomedical 489-96

beneficence 492

confidentiality 494-5

fidelity 494

good epidemiological practice 495-6

informed consent 490-1

justice 492-4

non-malfeasance 492

privacy 494-5

respect for autonomy 490

veracity 494

evidence-based medicine 149-50, 155

evidence-based practice 149-50

expected outcome 162, 164, 171, 388, 515

experimental designs

definition 216-23

multiple baseline 241

experimental studies 9

before-and-after controls 227-9

blind, double-blind and triple-blind trials 236-7

compliance and non-compliance 243-4

cross-over trial 238-9

definition of 218

design options 223-9

examples of 9-11

historic controls (non-current controls) 224-5

multiple baseline design 241

n-of-1 trial 239-40

randomisation 229-36

randomised control trial (RCT) 229, 234-6, 248

research-decided control group 226-7

study protocol 247-8

technical aspects 243-9

volunteer control group 226-7

Zelen's design 240-1

experiments and bias 358

exposure odds-ratio (EOR) 290-3, 333, 335, 350-1, 449

face-to-face interviews 407-8

falsifiability hypothesis 15-17, 22, 161-2

Farr, William 20-1

Feinstein, Alvan 7, 12, 170, 335-6, 342-3, 360, 462

fetal alcohol spectrum disorders (FASD) 451

fidelity 494

field trial 220-1

FINER (feasibility, interesting, novel, ethical and relevant) 153

fixed cohort 123-4, 297-8

Forge, John 497

forward directionality 261

Fracastoro, Girolamo 19-20

Framingham Heart Study 269

Freeman, Dick 484

Galton, Francis 419-20

Gendall, Philip 402

genetic carriers 57

germ theory of disease 5, 19-20, 42

Goldberger, Joseph 485

Gordis, Leon 387

Grady, Christine 498

Graham, Evarts 24, 27

Graunt, John 20

health 5

determinants of 179

public 6, 25-8, 503-6

health data

access 191-2

accuracy 186

appropriateness 187

Farrar, William 20-1

Feinstein, Alvan 7, 12, 170, 335-6, 342-3, 360, 462

Fetal alcohol spectrum disorders (FASD) 451

fidelity 494

field trial 220-1

FINER (feasibility, interesting, novel, ethical and relevant) 153

fixed cohort 123-4, 297-8

Forge, John 497

forward directionality 261

Fracastoro, Girolamo 19-20

Framingham Heart Study 269

Freeman, Dick 484

Galton, Francis 419-20

Gendall, Philip 402

genetic carriers 57

germ theory of disease 5, 19-20, 42

Goldberger, Joseph 485

Gordis, Leon 387

Grady, Christine 498

Graham, Evarts 24, 27

Graunt, John 20

health 5

determinants of 179

public 6, 25-8, 503-6

health data

access 191-2

accuracy 186

appropriateness 187
health data cont.
  completeness 186–7
  limitations of routine collected 185–8
  sources of routine 179–85
  timeliness 187
  use of routine sources of 182
  vital statistics 188–91
health data, routinely collected
  limitations 185–8
  sources of 179–85
  use of 182
health statistics, routine 178–85
health-related data 182
healthy worker effect 285, 337
*Helicobacter pylori* 52, 389
Henle, Friedrich 41–2, 45, 48
Henle and Koch's causality criteria 41–2
herd immunity 67–8, 70
hierarchy of evidence 155–6
Hill, Austin Bradford 6, 24, 27, 45–9, 229, 262, 271, 275, 301
Hills criteria of causality 266, 536, 544
Hippocrates 18–19
Hippocratic Oath 484
historic controls (non-concurrent controls) 224–5
HIV/AIDS 8, 51, 96–7, 99, 102, 103, 181, 187, 190, 204–5, 347, 495
Holland, Anthony 492
hospital discharge data 181
host (epidemiological triangle) 55–6
Huff, Darrell 324
Human Research Ethics Committee (HREC) 489, 499
human sexual response 404–5
Hwang Woo-suk 502

immunity 55, 66, 69
  herd 67–8, 70
incidence of disease frequency 119–29
  concept of ‘risk’ 128–9
  cumulative 120–3
  rate 123–8
  relationship between prevalence 129–33
  standard populations 147
incidence rate 119, 123–8, 131–2, 133–4, 139, 297–8
  age-specific 139
  age-standardised 176, 177–8
  characteristics of 127
  cumulative 121
  effects of imprecise times on 128
  formula to estimate 130
incubation period 38, 39–40, 57–8, 59, 61, 69
indirect standardised mortality rate (ISM) 138–9
infectious (communicable) disease
  basic and actual reproductive rate 66–7
biological agents 52–3
  concepts 50–2
  concepts in epidemiology 56–9
  epidemic curve 61–5
  epidemiology 4, 56–9, 65, 70
  herd immunity 67–8
  infectious/latent period 57–8
  modelling 65–8
  outbreaks 59–65
  simple 69–71
  transformation 51–2
  transition routes 56–7
infectious period 57–8
inferenceal statistics 433–4, 441–3
informed consent 233–4, 329, 330, 384, 486, 489, 490–2
information bias 325, 326, 338–44, 357, 358, 359, 363, 408, 533, 541
information seeking 157
instructions for authors 524
International Classification of Diseases (ICD) 21, 401
interview information, recording 408
interviews
  and data collection 406–8
  distant 407–8
  face-to-face 407–8
  information, recording 408
  types of 406–7
iodine deficiency 26–7
Jenner, Edward 19, 25
Johnson, Virginia 404–5
justice 492–4
Kant, Immanuel 504–5, 506
Kaposi's sarcoma 8
Koch, Robert 20, 41–2, 45, 48
Koch's causality criteria 41–2
Labaw, Patricia 402
latent period 57–8
*Legionella pneumophila* 62
liberalism 504–5
Lidcombe programme 539, 543
life expectancy 190–1
Likert scale 417
Lind, James 21, 224, 485
line of equality 85
literature review 17, 154–6
  critical appraisal 158–9
  information seeking 157
  practical tips on conducting 156–761
  writing 160–1
lung cancer 27–8
MacMahon, Brian 24
Mallon, Mary 42
Manhattan Project 497
masking (blinding) 236–7, 255, 358, 522
Masters, William 404–5
matching 280, 358, 359
in case-control studies 280–1
mathematical signs, symbols and abbreviations 480–1
Mead, Margaret 484
measure of central tendency 436, 437, 439
measure of dispersion 436, 437, 518
measures of association 287–303, 447
comparison between relative risk and difference measures 301
difference measures for cohort studies 298
difference measures in case-control studies 302
exposure odds-ratio (case–control studies) 290
prevalence odds-ratio (cross-sectional studies) 294
relative risk (closed cohort studies) 287
relative risk for dynamic and fixed cohorts 297
MEDLINE 154
Milgram experiment 486–7
Mill, John Stuart 504
modelling infectious diseases 65–8
basic and actual reproductive rate 66–7
defining factors of the basic reproductive rate 68
herd immunity 67–8
molecular epidemiology 44
moles, prevention in young Australians (case study) 219
multiple baseline design 241
multi-stage sampling 383
multivariable analysis 349, 358, 360, 462–8, 542
multivariable models 466
multivariable statistical analysis 462–8
data preparations; coding 463
data preparations; correlation matrix 462–3
presenting results 466–8
selecting an appropriate model 464–6
n-of-1 trial 239–40
Nambour Skin Cancer Study 269–70
National Ethics Application Form (NEAF) 489
National Notifiable Diseases Surveillance System 200
natural history of disease 6, 37–41, 218
necessary cause 42–3
negative predictive value 88–9, 90, 91–2, 95
Neisser, Albert 486
Newton, Isaac 497
non-compliance (experimental studies) 243–4
non-current controls (historic controls) 224–5
non-directionality 262
non-malfeasance 492
non-probability sampling 377, 385–7
non-scheduled standardised interview 408, 409
non-specific defence mechanisms 55
non-standardised interview 408, 409
number needed to treat (NNT) 247
numerical data 415, 436
numerical rating scale (NRS) 403, 416–17
numerical variable 439, 440, 458, 480
Nuremberg Code (1947) 485, 487–9
Nurses’ Health Study (NHS) 270–1
obsessive-compulsive disorder 442
observational studies 9, 217, 259–61, 524
examples of 9–11
observational study designs
case–control 265, 266, 273–81, 290–1, 294, 302–3, 304
cohort 265, 267–73, 287–90, 297–301
cross-sectional 265, 266, 281–7, 294–5
definition 259
directionality 261–2, 264–5, 266–7
hybrid 304
measures of association 287–303
nested case–control 304
three basic 265–87
timing 263–5, 266–7
observational uniformity 323, 358
observations
complete participation 405
and data collection 403–6
participant as observer 406
odds-ratio 349
confidence interval for exposure (EOR) 290–3, 333, 335, 350–1, 449
prevalence (POR) 294–6, 326, 332, 353–4, 362
operational research hypothesis 17, 149, 153, 161–5, 170, 171, 376, 388, 391, 451
ovarian cancer 262, 275–6
p value 452–3, 468, 518
participant as observer 406
passive surveillance 183
Pasteur, Louis 20, 42
peer-review process 524–5
percent attributable risk 299
percent population attributable risk 299
Pericles 5
period prevalence 115, 133
‘person’ characteristics of 173–5
PICOT (population, intervention, comparison, outcome and time frame) 153, 162, 172
Index 597
Index

placebo 9, 222, 234–6, 238–40, 246, 330, 358, 484
placebo effect 234, 236
‘place’ characteristics of 175–7
plagiarism 502
Plato 506
Pneumocystis carinii 8, 201
point prevalence 115, 117, 130–1
poliomyelitis 56, 222, 330–1, 384
Popper, Karl 14, 15
population at risk 54, 119, 120, 122–3, 124–5, 126, 128
population attributable risk 299
population mean, calculating the confidence interval for 443–5
Porter, Roy 36
positive predictive value 88–9, 90–1, 92, 95
Port, Percivall 21, 46
prevalence odds-ratio (POR) 294–6, 326, 332, 353–4, 362
prevalence of disease frequency 115–19
characteristics 117
point and period 115–17
relationship between incidence 129–33
standard populations 147
primary prevention 40
primary sampling units (PSUs) 383
privacy 494–5
probability sample 204
probability sampling 203, 377, 381, 384–5
protective data 401
psychiatric diagnosis 405
PsycINFO 154
public health 6
major achievements in 25–8
public health and ethical theory 503–6
communitarianism 503–6
liberalism 504–5
utilitarianism 503–4
publications, scientific 515–45
abstract, the 519–20
acknowledgements 520
consort checklist for randomised controlled trials 521–3
critical appraisal 529–45
discussion 519
formatting the manuscript 524
how to read 526–29
impact factor 525
instructions for authors 524
introduction 516–17
methodology 517–18
peer-review process 524–5
references 520
results 511–19
structure 515–24
technical aspects 524–5
title page 520
writing guidelines 521–4
PubMed 154
Pugh, Thomas 24
purposive sampling 386
Q Fever 38
quantiles 438–40
quality control research 7, 8–9
quality research 497
qualitative epidemiology 8
quantitative descriptive studies 170–2
cross-sectional studies 201–5
quantitative epidemiology 8, 9, 406
quantitative methods of data collection 399–424
adjectival scale 417
considerations for rating scales 418
the ‘don’t know’ problem 421
effect of wording on responses 422
face-to-face interviews vs distance interviews 407–8
features of a good question 412–14
format of responses 414–16
interviews 406–8
Likert scale 417
numerical rating scale (NRS) 416–17
observations 403–6
quality of data 400–3
questionnaire design 409, 411
questionnaire structure 409–10
questionnaires 408–19
recall loss 422–3
recording interview information 408
reliability 400
semantic differential scale 418–19
telemeping error 422–3
validating instruments 419–21
validity 400
vignettes 419
visual analogue scale (VAS) 416–17
what can go wrong 421–3
question(s)
closed-ended 414
contingencies of 412–13
open-ended 414
questionnaire design 409, 411
questionnaire structure 409–10
questionnaires and data collection 408–19
Radisch, Jack 493
radon error 321, 322–3, 326, 349, 433, 441–2, 451, 452
random sampling
simple 378–9
stratified 379–81
randomisation 229–36
randomised control trial (RCT) 229, 234–6
how to report 248
placebo controls 234–6
rates, standardisation of 132–9
recall loss 422–3
receiver operating characteristics (ROC) curve 99
referencing styles 520
relative risk (RR)
  confidence interval for 447–8
definition 288
reliability 83–6, 102, 319, 321–2, 376, 420, 441, 504
reliability of data 400
reproductive rate of infectious disease
  actual rate 66–7
  basic rate 66–7, 68
research, ethical concerns in clinical 498–9
research quality 497
research topic
  examples of possible 151–2
  selecting a 149–53
research-decided control group (experimental studies) 226–7
responsibility 496–7
rheumatic fever 25–6
rheumatic heart disease 25–6
risk
  average 128
  concept of 128–9
  factor 11, 27, 43, 155, 174, 192, 216, 217, 274, 299, 347, 348, 354
  population at 54, 119, 120, 122–3, 124–5, 126, 128
Rogers, Will 342–4
Rosenham, David 405
Ross River virus 40
routine collected health data 178–85
  access 191–2
  accuracy 186
  appropriateness 187
  completeness 186–7
  limitations 185–8
  sources 179–85
  timeliness 187
Russell, Bertand 14
Salk, Jonas 222, 330–1, 384
sample size and statistical confidence 387–92
sample size calculation 387–92
  prevalence estimated by a cross-sectional study 389–90
sampling
  cluster 382–5
  convenience 385, 396
  multi-stage 383
  non-probability 377, 385–7
  probability 377, 384–5
purposive 386
simple random 378–9
snowballing 157, 385–6
stratified random 379–81
systematic 381–2
techniques 376
sampling strategy 377–87
  cluster sampling 382–5
  non-probability 377, 385–7
  probability 377, 384–5
  simple random sampling 378–9
  stratified random sampling 379–81
  systematic sampling 381–2
scepticism 14
scheduled standardised interview 408
Schistosoma mansoni 57
scientific method 14–16
scientific misconduct 502–3
scientific publications 515–45
  abstract, the 519–20
  acknowledgements 520
  critical appraisal 529–45
  discussion 519
  formatting the manuscript 524
  how to read 526–29
  impact factor 525
  instructions for authors 524
  introduction 516–17
  methodology 517–18
  peer-review process 524–5
  references 520
  results 518–19
  structure 515–24
  technical aspects 524–5
  title page 520
  writing guidelines 521–4
screening for disease 100–5
  evaluation 103–5
  important issues 101–2
  programs 102–3
screening programs 102–3
  in Australia and New Zealand 103
secondary prevention 40
secular time trends 177
selection bias 325, 326, 328–38, 342
selective survival 336–7
self-administered questionnaires 409
self-selection bias 336–7
semantic differential scale 418–19
Semmelweis, Ignaz 20
sensitivity 86–7
sentinel surveillance 183
simple infectious disease model 67–71
simple random sampling 378–9
sleep studies 404
smallpox 25
smoking 27–8, 241–2
Snow, John 22–4, 60
snowballing sampling 157, 385–6
Socrates 503
sources, routine collected health data 179–85
specificity 86–7
specificity of association 47–8
standard deviation 437, 438
standard population (prevalence and incidence rates) 147
standardised mortality ratio (SMR) 138–9
standardisation of rates 132–9
  crude rates 133–5
  direct 135–6
  facts about 138–9
  indirect 136–8
  specific rates 133–5
  standard population 147
Stanford-Binet Intelligence Scales 420
statistical analysis
  and control bias 360
  multivariable 462–8
statistical hypothesis testing 451–9
statistical significance 450–1, 452–3
statistical testing
  bivariate 455–9
  errors in 453–4
statistical tests 452–3
statistics 433–70
  computer programs for data analysis 469
  and confidence interval 442–51
  descriptive 434, 436–41
  inferential 433–4, 441–3
  mathematical signs, symbols and abbreviations 480–1
  multivariable analysis 462–8
  pitfalls of agreement and equivalence 459–61
  and quantitative data 434–6
  routine collected health data 188–91
  and survival analysis 459
  vital 20, 188–91
stratified random sampling 379–81
study designs
  and selection bias 337–8
study protocol (experimental studies) 17, 247–8
surveillance 182–3
survival analysis 459
swine flu (H1N1 09) 113
syphilis 51, 56, 119, 120, 126–7, 133–4, 181, 486
systematic 341, 349
systematic error 321, 322–3, 324, 326, 339, 441
systematic review 155–6, 222, 254, 526
systematic sampling 381–2
Systemised Nomenclature of Medicine (SNOMED) 401
target population 203, 204, 269, 273, 281, 294, 319, 320–2, 323, 326, 328–9, 332–3, 340, 358, 359, 361, 376, 377–83, 385, 420–1, 433–4, 441, 454
telecosping error 422–3
temporality 47
tertiary prevention 40
therapeutical studies 218
'time' characteristics of 177–8
timeliness 187
timing (observational study design) 263–5, 266–7
tobacco 241–2
total fertility rate (TFR) 190
transmission routes 56–7
transition routes 56–7
triple-blind trials 236–7
Tumour–node–metastases (TNM) 343–4, 401
unit of analysis 172, 204
United States 25, 182, 190, 192, 200–1, 271, 336, 385–6, 420, 493, 502
utilitarianism 503–4
validating instruments 419–21
validity 83–4, 86–90, 102, 319, 321–4, 336, 376, 420, 441, 504
validity of data 359, 400
veracity 494
vignettes 419
visual analogue scale (VAS) 403, 416–17
vital statistics (routine collected health data) 20, 188–91
volunteer bias 104, 329–31
volunteer control group (experimental studies) 226–7
volunteer participation vs volunteer control group 226–7
wash-out time period 239
websites 72, 106, 141, 166, 206, 250, 393, 424, 471, 507, 545
Will Rogers phenomenon 342–4
Women’s Health Initiative (WHI) 246
World Health Organization (WHO) 5, 175, 191
writing guidelines for scientific publications 521–4
Wynder, Ernst Ludwig 24, 27
Zelen's design 240–1